This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
by Zacks Equity Research
Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.
BSXPositive Net Change ISRGPositive Net Change MEDPPositive Net Change CBLLPositive Net Change
medical medical-devices
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
by Zacks Equity Research
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
BSXPositive Net Change OSURPositive Net Change ATRCPositive Net Change SMTIPositive Net Change
medical medical-devices
Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?
by Moumi Mondal
HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.
DGXPositive Net Change HOLXPositive Net Change GEHCPositive Net Change
medical medical-devices
Should Labcorp Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.
LHPositive Net Change DGXPositive Net Change PAHCPositive Net Change BTSGPositive Net Change
medical medical-devices
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth
by Zacks Equity Research
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
BSXPositive Net Change ISRGPositive Net Change OPKPositive Net Change MEDPPositive Net Change
medical medical-devices
McKesson Builds Earnings Momentum on Specialty and Automation
by Zacks Equity Research
McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.
CAHPositive Net Change MCKPositive Net Change CVSPositive Net Change CORPositive Net Change
medical medical-devices
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
by Zacks Equity Research
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
MASIPositive Net Change VCYTPositive Net Change TCMDPositive Net Change AORTPositive Net Change
medical medical-devices
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
by Debanjana Dey
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
HIMSPositive Net Change DOCSNo Net Change TEMPositive Net Change
medical medical-devices
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
by Nalak Das
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
REGNPositive Net Change JNJPositive Net Change LLYPositive Net Change MDTPositive Net Change ISRGPositive Net Change
medical medical-devices pharmaceuticals
Hologic Trading Near 52-Week High: How Should You Play the Stock?
by Moumi Mondal
HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.
ABTPositive Net Change HOLXPositive Net Change COOPositive Net Change
medical medical-devices
CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
by Zacks Equity Research
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
OMCLPositive Net Change CVNegative Net Change SDGRPositive Net Change CCLDNegative Net Change
medical medical-devices
INBS Stock Surges 132.4% on New Manufacturing Partnership
by Zacks Equity Research
Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.
BSXPositive Net Change ISRGPositive Net Change MEDPPositive Net Change INBSNegative Net Change
medical medical-devices
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
ISRGPositive Net Change INGNPositive Net Change MEDPPositive Net Change SGHTNegative Net Change
medical medical-devices
Is it the Right Time to Add Insulet Stock to Your Portfolio?
by Zacks Equity Research
PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
DGXPositive Net Change PODDPositive Net Change PAHCPositive Net Change BTSGPositive Net Change
medical medical-devices
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.
BSXPositive Net Change ISRGPositive Net Change HQYPositive Net Change MEDPPositive Net Change
medical medical-devices
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
by Zacks Equity Research
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
BSXPositive Net Change ISRGPositive Net Change MEDPPositive Net Change CODXNegative Net Change
medical medical-devices
KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic
by Zacks Equity Research
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.
OMCLPositive Net Change KRMDPositive Net Change SDGRPositive Net Change CCLDNegative Net Change
medical medical-devices
ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery?
by Indrajit Bandyopadhyay
ISRG's single-port platform posts 91% procedure growth, led by Korea, with U.S. momentum building as new tools and indications expand adoption.
SYKPositive Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
by Zacks Equity Research
CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.
BSXPositive Net Change CNMDPositive Net Change ISRGPositive Net Change IDXXPositive Net Change
medical medical-devices
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
by Moumi Mondal
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
BSXPositive Net Change JNJPositive Net Change MDTPositive Net Change
medical medical-devices
Best Growth Stocks to Buy for December 31st
by Zacks Equity Research
GLDD, CIEN and PODD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 31, 2025.
CIENPositive Net Change PODDPositive Net Change GLDDNegative Net Change
communications construction medical-devices
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
by Zacks Equity Research
Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.
BSXPositive Net Change ISRGPositive Net Change MEDPPositive Net Change ESTAPositive Net Change
medical medical-devices
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
by Debanjana Dey
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
TDOCPositive Net Change HIMSPositive Net Change LFMDPositive Net Change
medical medical-devices
RBOT Enters Strategic Software Partnership to Streamline Development
by Zacks Equity Research
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
EDAPPositive Net Change VCYTPositive Net Change RBOTNegative Net Change AORTPositive Net Change
medical medical-devices
Tilly's (TLYS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TLYSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines